Across studies, FABP5 inhibition consistently attenuated malignant phenotypes, and FABP5-high HCC cells showed sensitivity to the FABP5 inhibitor SBFI-26, underscoring its potential as a robust therapeutic target in HCC [117,120,123]. The gene discussed is FABP5; the disease is hepatocellular carcinoma.